MedTrace Logo

AREG, EREG and EGFR: Response to Anti-EGFR Agents in Colorectal Cancer

NCT03986541 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 541

Last updated 2024-05-28

No results posted yet for this study

Summary

Observational study investigating the relationship between tumour amphiregulin, epiregulin and epithelial growth factor receptor expression and response to anti-EGFR agents in advanced colorectal cancer.

Conditions

  • Colorectal Cancer Stage IV

Interventions

DIAGNOSTIC_TEST

Immunohistochemistry

Assessment of tumour amphiregulin, epiregulin and EGFR expression by immunohistochemistry.

Sponsors & Collaborators

  • University of Liverpool

    collaborator OTHER

  • University of Manchester

    collaborator OTHER

  • Newcastle University

    collaborator OTHER

  • University of Nottingham

    collaborator OTHER

  • University of Sheffield

    collaborator OTHER

  • University of Leeds

    lead OTHER

Principal Investigators

  • Philip Quirke, PhD FRCPath · University of Leeds - Institute of Medical Research at St James's

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-23
Primary Completion
2022-02-22
Completion
2022-07-22

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03986541 on ClinicalTrials.gov